The Biotech Religion Invaded by Investor Skeptics
It has taken months for biotech's March madness to calm back into something like sanity, doing so in the context of Nasdaq's overall downward spiral. But if there was one lesson to the volume of recent financings it was this: the big can get bigger; the small-and the early-stage-should be just a teeny bit worried. The large and highly valued companies, particularly those with drugs on or about to be on the market can raise money easily. But new discovery-stage offerings have had trouble--like Rigel's. IPO buyers have instead opted for the apparently lower-risk, faster-return businesses of nearer-term companies like drug-delivery and service firms.
You may also be interested in...
There are many ways start-ups can lower the risks of doing business in the current climate. Amphora's approach will likely include working for hire to cool cash burn while building relationships with skittish clients; leveraging assets that have ripened beyond the research phase; and helping customers reduce the risks they confront.
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.